Orchid Pharma (ORCHPHARMA) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 sales reached ₹244.4 crore, up 34% year-over-year, driven by strategic initiatives and operational efficiency.

• EBITDA for Q1 FY25 was ₹41.0 crore, a 71% increase, with margin improving to 17% from 13% in Q1 FY24.

• Profit before tax (PBT) and profit after tax (PAT) both increased 169% year-over-year to ₹29.1 crore.

• Board approved unaudited standalone and consolidated financial results for Q1 FY2024-25, ended June 30, 2024.

• Launch of Orblicef (enmetazobactam + cefepime) in partnership with Cipla, with both companies marketing under separate brands.

Financial highlights

• Q1 FY25 revenue grew 34% year-over-year to ₹244.4 crore.

• EBITDA margin improved to 17% in Q1 FY25 from 13% in Q1 FY24.

• Gross margin for Q1 FY25 was 38.5%, slightly down from 38.7% in Q1 FY24.

• Employee expenses and other expenses as a percentage of sales were 8.8% and 16.2% respectively in Q1 FY25.

• Interest expense decreased 36% year-over-year to ₹3.5 crore in Q1 FY25.

Outlook and guidance

• Full-year revenue growth expected to moderate to 20–25%, in line with long-term guidance.

• Orblicef projected to reach ₹100 crore sales in 3–4 years for the AMS division; not expected to hit this in FY25.

• Royalty income from Europe expected to start in Q2 FY25, with cash flow lagging by one quarter.

• Company continues to focus on expansion and capital expenditure, including new manufacturing facilities.

• No major challenges foreseen in ongoing projects; optimism for sustained growth.